Login to Your Account

Clinic Roundup

Friday, July 8, 2011
Exelixis Inc., of South San Francisco, said that it will report results from its Phase III trial of cabozantinib in medullary cancer (EXAM) by about three months. That provides additional time to reach the prespecified number of progression-free survival events for unblinding.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription